Key result
Normalized stiffness plus cyclic stretch significantly reduces profibrotic protein production in HFrEF cardiac fibroblasts.
Why the study?
Normalization of hemodynamic load in heart failure with reduced ejection fraction does not reverse fibroblast activation or fibrosis due to a persistently altered fibroblast phenotype.
p-value: p=<0.01
Normalized substrate stiffness combined with cyclic stretch attenuates human cardiac fibroblast activation in HFrEF, suggesting a mechanistic pathway for reversing fibroblast phenotype.
Pulsatile LVAD concepts may attenuate fibroblast activation; leaves open clinical translation and requires prospective validation.
AIMS: Elevated hemodynamic load in heart failure (HF) activates fibroblasts and increases collagen deposition, but normalization of load (as occurs with current nonpulsatile left ventricular assist device (LVAD) support) does not reverse fibroblast activation or fibrosis, attributable to a persistently altered fibroblast phenotype. We hypothesized that the combination of reduced load and cyclic stretch in vitro (equivalent to pulsatile LVAD therapy in vivo) would attenuate fibroblast activation. METHODS AND RESULTS: Myocardium from subjects with HF (n = 15) with reduced ejection fraction (HFrEF) and from unused donor hearts (control, n = 5) was used to assess collagen content and for human cardiac fibroblasts (HCF) isolation. HCFs were cultured on substrates with stiffness representing normal (1 kPa) or HFrEF (10 kPa) myocardium and were exposed to 48 hours of cyclic stretch or left unstretched. Alterations in protein production and transcriptional expression in control and HFrEF fibroblasts were assessed. Collagen content was significantly greater in HFrEF tissue than control (6.7% vs 2.1%, p < 0.01). In contrast to control, HFrEF HCFs showed no difference in collagen 1α(I), TIMP1, and αSMA production on 1 vs 10 kPa substrates without cyclic stretch; however, HFrEF HCFs with cyclic stretch produced less collagen1α(I), TIMP1, and αSMA on 1 kPa but not 10 kPa substrates (all p < 0.01). Bulk ribonucleic acid sequencing analysis identified dysregulated pathways in force sensing/signaling in HFrEF HCFs, that, on 1 kPa with stretch, were altered towards that of controls. CONCLUSION: These novel results in primary HCFs demonstrate that normalized substrate stiffness combined with cyclic stretch attenuated HCF activation and identified associated mechanistic pathways for reversing fibroblast phenotype in patients with HF.
No takes yet. Share an insight, caveat, or question.
Silverman et al. (2025) studied Heart failure with reduced ejection fraction (n=20). Cyclic stretch on normal stiffness (1 kPa) substrates vs. Unstretched or 10 kPa substrates was evaluated on Production of collagen 1α(I), TIMP1, and αSMA (p=<0.01). In human cardiac fibroblasts from HFrEF patients, normalized substrate stiffness combined with cyclic stretch significantly reduced collagen 1α(I), TIMP1, and αSMA production (p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: